Prot #OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration

Project: Research project

Project Details

StatusFinished
Effective start/end date11/29/1611/29/19

Funding

  • Chiltern International, Inc. (Prot #OHR-1601 // Prot #OHR-1601)
  • Ohr Pharmaceutical, Inc. (Prot #OHR-1601 // Prot #OHR-1601)